Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $85000.0.

  • Palisade Bio's Share-based Compensation fell 760.87% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $291000.0, marking a year-over-year decrease of 6135.46%. This contributed to the annual value of $652000.0 for FY2024, which is 448.72% up from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's Share-based Compensation is $85000.0, which was down 760.87% from $60000.0 recorded in Q2 2025.
  • In the past 5 years, Palisade Bio's Share-based Compensation ranged from a high of $569000.0 in Q1 2021 and a low of $60000.0 during Q2 2025
  • Over the past 5 years, Palisade Bio's median Share-based Compensation value was $131000.0 (recorded in 2023), while the average stood at $204000.0.
  • Examining YoY changes over the last 5 years, Palisade Bio's Share-based Compensation showed a top increase of 64974.96% in 2021 and a maximum decrease of 8448.8% in 2021.
  • Over the past 5 years, Palisade Bio's Share-based Compensation (Quarter) stood at $103000.0 in 2021, then decreased by 16.5% to $86000.0 in 2022, then skyrocketed by 115.12% to $185000.0 in 2023, then crashed by 58.38% to $77000.0 in 2024, then rose by 10.39% to $85000.0 in 2025.
  • Its last three reported values are $85000.0 in Q3 2025, $60000.0 for Q2 2025, and $69000.0 during Q1 2025.